Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Quoin Pharmaceuticals, Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 PRIVATE PLACEMENT FINANCING OF UP TO $105.3 MILLION CLOSED IN OCTOBER 2025 TO FUND OPERATIONS AND R&D  SALLY LAWLOR APPOINTED CFO TO SUPPORT COMMERCIALIZATION AND FINANCIAL OPERATIONS  ORPHAN DRUG DESIGNATION AWARDED BY FDA TO QRX003 FOR NETHERTON SYNDROME  PEDIATRIC NETHERTON CLINICAL PROGRAM EXPANDED BASED ON POSITIVE LONG-TERM SAFETY AND EFFICACY DATA  QRX003 PIVOTAL STUDIES TO COMMENCE ENROLLMENT IN Q4 2025  NETHERTON NOW AWARENESS CAMPAIGN VIDEOS ACHIEVE OVER 1.5 MILLION VIEWS IN 6 MONTHS SINCE LAUNCH.  POSITIVE PEELING SKIN DATA AND STUDY EXPANSION PLANS RELEASED ASHBURN, VA.

QUOIN PHARMACEUTICALS ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2025 FINANCIAL RESULTS

ASHBURN, VA., OCT. 30, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (THE "COMPANY" OR "QUOIN"), A LATE CLINICAL-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND ORPHAN DISEASES, TODAY ANNOUNCED THAT IT PLANS TO PROVIDE AN OPERATIONAL UPDATE HIGHLIGHTING KEY ACHIEVEMENTS FROM THE QUARTER, RECENT ACCOMPLISHMENTS, AND FINANCIAL HIGHLIGHTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, BEFORE THE MARKET OPENS ON THURSDAY, NOVEMBER 6, 2025.

QUOIN PHARMACEUTICALS TO PROVIDE CORPORATE UPDATE AND ANNOUNCE THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 6, 2025

PIPE FINANCING INCLUDED PARTICIPATION FROM LEADING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS INCLUDING AIGH CAPITAL MANAGEMENT, SOLEUS CAPITAL, NANTAHALA CAPITAL, DIADEMA PARTNERS, STONEPINE CAPITAL MANAGEMENT, ADAR1 CAPITAL MANAGEMENT, AND VELAN CAPITAL, AMONG OTHERS PIPE FINANCING INCLUDED PARTICIPATION FROM LEADING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS INCLUDING AIGH CAPITAL MANAGEMENT, SOLEUS CAPITAL, NANTAHALA CAPITAL, DIADEMA PARTNERS, STONEPINE CAPITAL MANAGEMENT, ADAR1 CAPITAL MANAGEMENT, AND VELAN CAPITAL, AMONG OTHERS

QUOIN PHARMACEUTICALS ANNOUNCES PRIVATE PLACEMENT FINANCING OF UP TO $104.5 MILLION

NEW EPISODE HIGHLIGHTS THE SOCIAL AND EMOTIONAL IMPACT OF NETHERTON SYNDROME, THE IMPORTANCE OF SUPPORTIVE COMMUNITIES, AND THE URGENT NEED FOR AN APPROVED TREATMENT NEW EPISODE HIGHLIGHTS THE SOCIAL AND EMOTIONAL IMPACT OF NETHERTON SYNDROME, THE IMPORTANCE OF SUPPORTIVE COMMUNITIES, AND THE URGENT NEED FOR AN APPROVED TREATMENT

QUOIN PHARMACEUTICALS RELEASES FIFTH NETHERTON NOW VIDEO FEATURING WRITERS AND INFLUENCERS ALLIE AND KALEIGH FASANELLA, TWIN SISTERS LIVING WITH NETHERTON SYNDROME

ASHBURN, VA., AUG. 18, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (QUOIN OR THE COMPANY), A LATE CLINICAL STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND ORPHAN DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF ITS NEW CHIEF FINANCIAL OFFICER AS THE COMPANY ADVANCES ITS LEAD PRODUCT CANDIDATE, QRX003, THROUGH PIVOTAL CLINICAL STUDIES AND PREPARES FOR POTENTIAL COMMERCIALIZATION.

QUOIN PHARMACEUTICALS APPOINTS NEW CHIEF FINANCIAL OFFICER TO SUPPORT COMMERCIALIZATION STRATEGY

NEW EPISODE HIGHLIGHTS THE PAINFUL, OFTEN MISUNDERSTOOD REALITY OF LIVING WITH NETHERTON SYNDROME AND THE URGENT NEED FOR EFFECTIVE TREATMENTS NEW EPISODE HIGHLIGHTS THE PAINFUL, OFTEN MISUNDERSTOOD REALITY OF LIVING WITH NETHERTON SYNDROME AND THE URGENT NEED FOR EFFECTIVE TREATMENTS

QUOIN PHARMACEUTICALS RELEASES FOURTH EPISODE IN NETHERTON NOW VIDEO SERIES FEATURING INTERNATIONAL PATIENT ADVOCATE MANDY ALDWIN-EASTON

LEAD PRODUCT, QRX003, BEING TESTED IN TWO ACTIVE REGISTRATIONAL CLINICAL STUDIES FOR NETHERTON SYNDROME ACROSS THE U.S., EUROPE, AND THE MIDDLE EAST.

QUOIN PHARMACEUTICALS PROVIDES PRODUCT PORTFOLIO UPDATE

COMPANY CONTINUES TO ADVANCE QRX003 IN LATE-STAGE CLINICAL TRIALS IN NETHERTON SYNDROME PATIENTS REGULATORY MILESTONE PROVIDES 10 YEARS OF MARKET EXCLUSIVITY IN EUROPE UPON APPROVAL ASHBURN, VA., MAY 20, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS ANNOUNCES EUROPEAN MEDICINES AGENCY (EMA) GRANTS ORPHAN DRUG DESIGNATION FOR QRX003 FOR THE TREATMENT OF NETHERTON SYNDROME

ASHBURN, VA., MAY 14, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (THE COMPANY OR QUOIN), A LATE CLINICAL STAGE, SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND ORPHAN DISEASES, TODAY ANNOUNCES POSITIVE INITIAL CLINICAL DATA FROM ITS ONGOING INVESTIGATOR PEDIATRIC PEELING SKIN SYNDROME CLINICAL STUDY.

QUOIN PHARMACEUTICALS ANNOUNCES INITIAL POSITIVE CLINICAL DATA FOR QRX003 FROM PEDIATRIC PEELING SKIN SYNDROME STUDY

ASHBURN, VA., APRIL 30, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (THE COMPANY OR QUOIN), A LATE CLINICAL STAGE, SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF THERAPEUTIC PRODUCTS THAT TREAT RARE AND ORPHAN DISEASES, TODAY ANNOUNCES THAT IT HAS RECEIVED WRITTEN NOTICE FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC (NASDAQ) STATING THAT THE COMPANY HAS REGAINED COMPLIANCE WITH THE MINIMUM BID PRICE REQUIREMENT UNDER NASDAQ LISTING RULE 5550(A)(2).

Quoin Pharmaceuticals, Ltd.

QNRX

Price

Financial Reports

No items found.

Press Releases

Quoin Pharmaceuticals, Ltd.

QNRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

QNRX